Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation
- PMID: 19188144
- PMCID: PMC2666541
- DOI: 10.1158/1078-0432.CCR-08-2235
Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation
Abstract
Increased polyamine synthesis and inflammation have long been associated with colon carcinogenesis in both preclinical models and in humans. Recent experimental studies suggest that polyamines may be mechanistically involved in colonic inflammatory processes. Genetic epidemiology results indicate that a single nucleotide polymorphism influencing the expression of a polyamine biosynthetic gene is associated with both risk of colon polyp occurrence and recurrence, and the response to aspirin as a polyp preventive agent. A prospective, randomized, placebo-controlled clinical trial of combination difluoromethylornithine, a selective inhibitor of polyamine synthesis, and sulindac, a nonsteroidal anti-inflammatory drug, found that the 3-year treatment was associated with a 70% reduction of recurrence of all adenomas, and over a 90% reduction of recurrence of advanced and/or multiple adenomas, without evidence of serious toxicities. This proof-of-principle trial indicates that targeting polyamine synthesis and inflammation can be an effective strategy for preventing the occurrence of the advanced and/or multiple adenomas that are most closely associated with the development of colon cancers in humans.
Figures

References
-
- Gerner EW, Meyskens FL., Jr Polyamines and cancer: old molecules, new understanding. Nature Reviews Cancer. 2004;4:781–92. - PubMed
-
- Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc. 1976;35:1332–8. - PubMed
-
- Sporn MB. Combination chemoprevention of cancer. Nature. 1980;287:107–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA023074/CA/NCI NIH HHS/United States
- N01 CN075019/CN/NCI NIH HHS/United States
- CA23074/CA/NCI NIH HHS/United States
- R01 CA123065/CA/NCI NIH HHS/United States
- CA123065/CA/NCI NIH HHS/United States
- P01 CA072008/CA/NCI NIH HHS/United States
- P30 CA062203/CA/NCI NIH HHS/United States
- R01 CA088078/CA/NCI NIH HHS/United States
- R01 CA059024/CA/NCI NIH HHS/United States
- CA72008/CA/NCI NIH HHS/United States
- CA95060/CA/NCI NIH HHS/United States
- CA47396/CA/NCI NIH HHS/United States
- CA88078/CA/NCI NIH HHS/United States
- P50 CA095060/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources